Protective immunity is about more than just an initial immune response; in fact, its also about how patients’ may respond to an infectious agent over time, stay protected, and fight of re-infection or reactivation of disease. Here at Virax Biolabs, we specialize in levegraging cutting-edge molecular techniques to help you explore patient immune landscapes. Our […]
T cell stimulation assays play an important role in modern immunology research. Not only are they useful tools in infectious disease and cancer immunotherapy studies, but they’re also critical aspects in various vaccine and drug development pipelines. Assays such as ELISpot, FluoroSpot and intracellular cytokine staining (ICS) are cornerstones of this effort, allowing researchers the […]
Myalgic encephalomyelitis (ME/CFS), also known as chronic fatigue syndrome, is a complex condition characterized by post-exertional fatigue and a range of neuroimmune symptoms. It is one of several debilitating conditions that fall under the diagnostic umbrella of post-acute infection syndrome (PAIS) due to its association with an incomplete recovery from viral disease. ME/CFS often […]
LONDON, Oct. 23, 2024 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company’s ImmuneSelect Research Use portfolio in the United […]
